Vericel Q2 revenue rises 15% to $52.7M; MACI up 21%; raises FY2024 margin guidance to 71%

Vericel Corp

2024-Q2 EPS reported -$0.18 revenue$103,943,000

MACI net revenue $44.1M (+21% YoY); NexoBrid revenue $0.8M (+76% QoQ); Burn Care franchise total $8.5M.
Gross margin 70% (up 430bps); adjusted EBITDA $6.3M (+42%), margin 12% (up 230bps).
FY2024 guidance reaffirmed: revenue $238-242M; gross margin raised to 71%, adjusted EBITDA margin to 21%.
MACI Arthro launch expected later Q3 2024; NexoBrid pediatric FDA approval anticipated in Q3 2024.
Net loss $4.7M ($0.10 diluted EPS) vs $5.0M loss in prior year; cash $154M, no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.